Edition:
India

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

18.68HKD
10:32am IST
Change (% chg)

HK$0.98 (+5.54%)
Prev Close
HK$17.70
Open
HK$17.84
Day's High
HK$18.78
Day's Low
HK$17.84
Volume
4,810,062
Avg. Vol
13,577,872
52-wk High
HK$23.25
52-wk Low
HK$9.35

Latest Key Developments (Source: Significant Developments)

3SBio Announces Tpiao Injection gets Approval For Clinical Trials For Additional Indication By CFDA
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - 3SBio Inc <1530.HK>::TPIAO INJECTION GRANTED APPROVAL FOR CLINICAL TRIALS FOR ADDITIONAL INDICATION BY CHINA FOOD AND DRUG ADMINISTRATION​.  Full Article

3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​
Monday, 15 Jan 2018 

Jan 15 (Reuters) - 3Sbio Inc <1530.HK>::UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820​.  Full Article

3SBio Says ‍China FDA Approves New Once-Weekly Bydureon To Improve Glycemic Control​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - 3Sbio Inc <1530.HK>::‍CHINA FDA APPROVES NEW ONCE-WEEKLY BYDUREON TO IMPROVE GLYCEMIC CONTROL​.  Full Article

3SBio Inc says 601a approved by China FDA for clinical trials ​
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - 3SBio Inc <1530.HK>:Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​.  Full Article

3Sbio says HY net profit rose about 34.3 pct
Monday, 28 Aug 2017 

Aug 28 (Reuters) - 3Sbio Inc <1530.HK>::HY revenue up 30.8 pct to about RMB1,706.7 million.HY net profit rose about 34.3 pct to about RMB389.6 million.No dividends were declared or paid by the company during the six months ended 30 June 2017.  Full Article

BRIEF-3SBio Inc plans to issue 300 mln euros convertible bonds
Thursday, 13 Jul 2017 

Corrects incomplete headline to add details about bond issue:Proposed Issue Of Euro 300,000,000 Zero Coupon Convertible Bonds Due 2022 .Net proceeds from bonds (after deduction of commissions and other related expenses) are estimated to be approximately 294.9 million euros.  Full Article

3Sbio inc -
Thursday, 13 Jul 2017 

July 13 (Reuters) - 3sbio Inc <1530.HK>:Proposed Issue Of Euro300,000,000 Zero Coupon Convertible Bonds Due 2022 .Net proceeds from bonds (after deduction of commissions and other related expenses) are estimated to be approximately 294.9 million euros.  Full Article

3SBio Inc TPIAO being received approval for drug clinical trials
Friday, 9 Jun 2017 

June 9 (Reuters) - 3SBio Inc <1530.HK>:TPIAO, one of products of group, has been granted approval for drug clinical trials for additional indications issued by china food and drug administration.  Full Article

3Sbio Inc updates on marketing authorization for group's product EPIAO
Friday, 9 Jun 2017 

June 9 (Reuters) - 3Sbio Inc <1530.HK> ::Group has received marketing authorization for group's product EPIAO from ministry of health of Ukraine.  Full Article

3Sbio Inc enters distribution and promotion agreement with two subsidiaries of Eli Lilly
Tuesday, 16 May 2017 

May 16 (Reuters) - 3sbio Inc <1530.HK>:Enters distribution and promotion agreement with two subsidiaries of Eli Lilly and co for distribution and promotion of insulin products.Co has been granted exclusive right of distribution and promotion of Humulin, an insulin product of Lilly, in China from July 1, 2017.3Sbio will establish a marketing and promotion team which will cover a wide array of diabetes products, including Humulin.  Full Article

BRIEF-3SBio Announces Tpiao Injection gets Approval For Clinical Trials For Additional Indication By CFDA

* TPIAO INJECTION GRANTED APPROVAL FOR CLINICAL TRIALS FOR ADDITIONAL INDICATION BY CHINA FOOD AND DRUG ADMINISTRATION​ Source text for Eikon: Further company coverage: